{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:29:28Z","timestamp":1794475768972,"version":"4.9.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ygyno.2026.04.020","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T20:43:36Z","timestamp":1778186616000},"page":"62-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Expression of the antibody-drug conjugate targets TROP2, CLDN6, B7-H3, and DLL3 in mesonephric-like adenocarcinoma of the female genital tract"],"prefix":"10.1016","volume":"209","author":[{"given":"Xiaoming","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahanbanoo","family":"Shahryari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandra G.","family":"Kingsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Glenn","family":"McCluggage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke E.","family":"Howitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2026.04.020_bb0005","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/his.12895","article-title":"Hormone receptor-negative, thyroid transcription factor 1-positive uterine and ovarian adenocarcinomas: report of a series of mesonephric-like adenocarcinomas","volume":"68","author":"McFarland","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.ygyno.2026.04.020_bb0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pathol.2017.11.084","article-title":"Mesonephric proliferations of the female genital tract","volume":"50","author":"Howitt","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.ygyno.2026.04.020_bb0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/PGP.0000000000001150","article-title":"Mesonephric-like adenocarcinoma (MLA) diagnostic criteria and controversies: perspectives and guidance from pathologists in the MLA consortium","volume":"45","author":"Mills","year":"2026","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0020","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438582","article-title":"Updates in the use of targeted therapies for gynecologic cancers","volume":"44","author":"Cantillo","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.ygyno.2026.04.020_bb0025","article-title":"Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma","volume":"37","author":"Shen","year":"2021","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2024.01.015","article-title":"Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: a single-center experience with molecular characterization, treatment, and oncologic outcomes","volume":"182","author":"Praiss","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0035","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/10668969231183631","article-title":"Ovarian mesonephric-like adenocarcinoma with recurrent liver metastases: a case report with analysis of therapeutic molecular targets","volume":"32","author":"Sugitani","year":"2024","journal-title":"Int. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0040","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/GCO.0000000000001002","article-title":"Antibody-drug conjugates as targeted therapy for treating gynecologic cancers: update 2025","volume":"37","author":"Silverstein","year":"2025","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0050","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2026.04.020_bb0055","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in metastatic triple-negative breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0060","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1200\/JCO.23.02767","article-title":"Efficacy and safety of Sacituzumab Govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer","volume":"42","author":"Santin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0065","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2024.5424","article-title":"Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (review)","volume":"54","author":"Katoh","year":"2024","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0070","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0075","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: an attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0080","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0085","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0090","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000043110","article-title":"The prognostic and therapeutic potential of Claudin-6 and Trop-2 expression as targeted biomarkers in serous ovarian cancer: an observational study","volume":"104","author":"Yuceer","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ygyno.2026.04.020_bb0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12022-025-09854-3","article-title":"DLL3 expression in neuroendocrine carcinomas and neuroendocrine tumours: insights from a multicentric cohort of 1294 pulmonary and extrapulmonary neuroendocrine neoplasms","volume":"36","author":"Schmitt","year":"2025","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0100","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2147\/ITT.S521008","article-title":"Preclinical evaluation of a B7-H3 targeting antibody enhancing NK cell-mediated cytotoxicity for ovarian cancer treatment","volume":"14","author":"Hagelstein","year":"2025","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0105","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ejca.2009.12.019","article-title":"Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients","volume":"46","author":"Bignotti","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2026.04.020_bb0110","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0115","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","article-title":"Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors","volume":"26","author":"Theruvath","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.659662","article-title":"B7-H3 as a target for CAR-T cell therapy in skull base chordoma","volume":"11","author":"Long","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0125","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/1538-7445.AM2022-330","article-title":"Abstract 330: targeting B7-H3 in prostate cancer: preclinical proof of concept with MGC018, an investigational anti-B7-H3 antibody-drug conjugate","volume":"82","author":"Scribner","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0130","first-page":"S548","article-title":"715MO safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study","volume":"35","author":"Wang","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0135","doi-asserted-by":"crossref","first-page":"367","DOI":"10.21873\/invivo.13837","article-title":"Clinicopathological significance of Claudin-6 immunoreactivity in low-grade, early-stage endometrioid endometrial carcinoma","volume":"39","author":"Lee","year":"2025","journal-title":"In Vivo"},{"key":"10.1016\/j.ygyno.2026.04.020_bb0140","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.ygyno.2026.04.020_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.734901","article-title":"Delta-like protein 3 expression in paired Chemonaive and Chemorelapsed small cell lung Cancer samples","volume":"8","author":"Kuempers","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.729765","article-title":"Prevalence of Delta-like protein 3 in a consecutive series of surgically resected lung neuroendocrine neoplasms","volume":"11","author":"Al\u00ec","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0155","series-title":"Female genital tumours","author":"WHO Classification of Tumours Editorial Board","year":"2020"},{"key":"10.1016\/j.ygyno.2026.04.020_bb0160","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/1878-0261.12627","article-title":"Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo","volume":"14","author":"Perrone","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0165","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1200\/JCO.2023.41.16_suppl.5599","article-title":"Preliminary results of a phase II trial with Sacituzumab Govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2","volume":"41","author":"Santin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0170","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/modpathol.2010.95","article-title":"Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas","volume":"23","author":"Zang","year":"2010","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0175","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ygyno.2011.09.012","article-title":"Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis","volume":"124","author":"Brunner","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0180","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.2174\/0929867326666190517115515","article-title":"B7-H3 immune checkpoint protein in human cancer","volume":"27","author":"Flem-Karlsen","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0185","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2026.04.020_bb0190","doi-asserted-by":"crossref","DOI":"10.1186\/1746-1596-8-190","article-title":"Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases \u22122 expression in ovarian carcinoma","volume":"8","author":"Wang","year":"2013","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0195","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013442","article-title":"Upregulated delta-like protein 3 expression is a diagnostic and prognostic marker in endometrial cancer: a retrospective study","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.ygyno.2026.04.020_bb0200","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/PAS.0000000000000958","article-title":"Targeted genomic profiling reveals recurrent KRAS mutations in mesonephric-like adenocarcinomas of the female genital tract","volume":"42","author":"Mirkovic","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0205","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1158\/2159-8290.CD-17-1461","article-title":"Mechanisms of oncogene-induced replication stress: jigsaw falling into place","volume":"8","author":"Kotsantis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0210","article-title":"Antibody drugs conjugates in small-cell lung cancer: present-day status and promises","volume":"30","author":"Syal","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2026.04.020_bb0215","article-title":"Antibody-drug conjugates in colorectal cancer: advances in targeted delivery and personalized oncology","volume":"14","author":"Wang","year":"2026","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ygyno.2026.04.020_bb0220","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2026.15576","article-title":"Targeting TROP-2 in treatment-resistant non-small cell lung cancer harboring the KRAS G12C mutation and TROP-2 upregulation: a case report","volume":"31","author":"Sun","year":"2026","journal-title":"Oncol. Lett."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826019748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826019748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:59:48Z","timestamp":1794473988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826019748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":44,"alternative-id":["S0090825826019748"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.04.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of the antibody-drug conjugate targets TROP2, CLDN6, B7-H3, and DLL3 in mesonephric-like adenocarcinoma of the female genital tract","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}